CTOs on the Move

Shattuck Labs

www.shattucklabs.com

 
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck`s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company`s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Abhinav Shukla
 Chief Technical Officer Profile

Funding

Shattuck Labs raised $118M on 06/15/2020

Similar Companies

Farkas IRM

Farkas IRM is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shenandoah Biotechnology

Shenandoah Biotechnology is a Warminster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precision Diagnostics

Precision Diagnostics, a leader in clinical laboratory testing and medication adherence monitoring, is transforming healthcare through the delivery of comprehensive, insightful clinical data that can help improve patient outcomes and manage costs. Spec...

Infectious Disease Research Institute

IDRI is a nonprofit biotech organization taking a comprehensive approach to develop new solutions for infectious disease. We combine the high-quality science of a research or academic organization with the product development capabilities of a life science company, including an onsite GMP manufacturing facility.

Elevation Oncology

Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor`s unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion.